Research into efficient and effective drug delivery systems is important in the development of medicines and the future of a personalised approach to treatments. Being able to encapsulate a drug for controlled release has advantages including lower dosage, reduced side-effects, and improved results of the treatment.

Dolomite’s continuous flow, microfluidic method overcomes these obstacles, providing almost 100% encapsulation within precisely controlled, monodisperse PLGA particles, in a reproducible way.

Monodisperse and Uniform Particles

For drug encapsulation to be effective, it’s important that the size, shape, and architecture of the particle is precise and reproducible.
Conventional methods however often result in uneven API distribution and particle polydispersity.

  • Small average size and narrow size distributions
  • Monodisperse (CV 5%)
  • Uniform morphology

Larger Size Range with a Narrow Distribution

Create smaller particles across a wider range of sizes. Using the traditional batch method results in uneven API distribution and particle polydispersity. This then requires size-selection, leading to low particle yields, wastage and significant loss of API.

Continuous synthesis of PLGA particles in a microfluidic chip. (25% playback speed)

My work is mainly focused on using different polymers, particularly PLGA – poly(lactic-co-glycolic acid) – for drug encapsulation, generating monodisperse particles for further investigation … The classical method of encapsulating drugs usually involves an extrusion step to produce particles of uniform size, but this can be avoided by using a microfluidic chip … I use a Dolomite system for this purpose, preparing particles on an almost daily basis, and find it very straightforward.

Dr Samar Damiati

King Abdulaziz University, Saudi Arabia

Traditional polymer encapsulation delivery systems rely on diffusion or breakdown of the polymer to release their payload…microfluidics offers better control of particle size and a high yield of monodisperse emulsion. As the resulting material does not need to be screened to remove incorrectly-sized particles, this minimizes waste and increases yield by as much as 30 percent.

Jeff Henise

Director of Process Development, ProLynx

Traditional Methods (Batch) Microfluidics
Encapsulation Efficiency

How much of the drug is loaded into the particle during encapsulation.

~30% ~100%
Particle Size Distribution

Number of particles (by mass) according to particle size.

20% 5%

The amount of overall particles produced to the specification required vs. the number of particles not meeting required specification and going to waste.

~50% None

The ability for the entire experiment to be duplicated and recieve the same results.

Low High
API Mixing

The level to which API is distributed throughout the particles produced.

Uneven Uniform
Particle Size Control

Ability to adjust experimental parameters to achive precise control of the particle size.

Poor Precise
For over 15 years, we have been developing microfluidic technologies to enable efficient microencapsulation. We understand that uniform API distribution, reproducibility and the ability to scale up are critical in drug delivery applications. With Dolomite technology, microencapsulation has never been easier.  
Mark Gilligan – CEO, Dolomite Microfluidics

Further Reading

in thenews

Drug Delivery Studies

A Dolomite microfluidic system is helping Dr Samar Damiati, Assistant Professor in the Biochemistry Department at King Abdulaziz University in Saudi Arabia, perform drug encapsulation studies.


Continuous Synthesis of PLGA Nanoparticles

Methodology for fabrication of monodisperse PLGA beads with sizes ranging from 50 nm to 30μm using the Hydrodynamic Flow Focusing Method.


Continuous Synthesis of PLGA Microparticles

Methodology for fabrication of highly monodisperse PLGA beads with sizes ranging from 10 to 45μm using the Droplet Method.

Speak to a Microfluidics Expert